Bicara Therapeutics Inc. Common Stock (BCAX) - Total Liabilities
Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has total liabilities worth $39.64 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Bicara Therapeutics Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.
Bicara Therapeutics Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Bicara Therapeutics Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Alpha Animation and Culture Co Ltd
SHE:002292
|
China | CN¥1.14 Billion |
|
Hycroft Mining Holding Corporation
NASDAQ:HYMC
|
USA | $46.10 Million |
|
Minda Corporation Limited
NSE:MINDACORP
|
India | Rs27.42 Billion |
|
China National Building Material Company Limited
F:D1Y
|
Germany | €303.13 Billion |
|
Kumho Petro Chemical
KO:011780
|
Korea | ₩2.23 Trillion |
|
Gansu Qilianshan Cement Group Co Ltd
SHG:600720
|
China | CN¥13.31 Billion |
|
Punjab & Sind Bank
NSE:PSB
|
India | Rs1.65 Trillion |
|
Stolt-Nielsen Limited
OL:SNI
|
Norway | Nkr3.36 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Bicara Therapeutics Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BCAX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bicara Therapeutics Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bicara Therapeutics Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Bicara Therapeutics Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $29.54 Million | -61.79% |
| 2024-12-31 | $77.32 Million | +399.68% |
| 2023-12-31 | $15.47 Million | -35.47% |
| 2022-12-31 | $23.98 Million | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more